Segment Reporting – Pharmaceuticals |
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||
|
Merck Serono |
Consumer Health Care |
||||||||||
EUR million |
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||
|
||||||||||||
Sales |
1,305.9 |
1,235.9 |
3,991.3 |
3,695.5 |
124.7 |
122.8 |
344.9 |
333.0 |
||||
Royalty and commission income* |
87.6 |
82.8 |
259.5 |
256.8 |
0.3 |
0.1 |
1.5 |
1.6 |
||||
Total revenues |
1,393.5 |
1,318.6 |
4,250.7 |
3,952.3 |
125.0 |
122.9 |
346.4 |
334.6 |
||||
Gross margin |
1,199.8 |
1,099.4 |
3,605.1 |
3,327.0 |
86.3 |
86.6 |
237.5 |
231.2 |
||||
Marketing and selling expenses* |
–345.6 |
–315.0 |
–1,046.8 |
–970.7 |
–55.5 |
–51.3 |
–175.3 |
–151.7 |
||||
Royalty and commission expenses* |
–110.4 |
–102.3 |
–340.4 |
–295.4 |
–0.3 |
–0.3 |
–1.0 |
–1.1 |
||||
Administration expenses |
–66.9 |
–63.8 |
–198.2 |
–196.6 |
–6.9 |
–6.3 |
–18.8 |
–18.9 |
||||
Other operating expenses and income |
–39.4 |
–58.1 |
–159.3 |
–141.0 |
–0.9 |
–2.3 |
–10.7 |
–4.2 |
||||
Research and development |
–279.6 |
–293.2 |
–880.2 |
–867.4 |
–5.5 |
–4.2 |
–16.4 |
–12.8 |
||||
Operating result |
209.5 |
123.4 |
551.1 |
423.8 |
16.2 |
21.4 |
12.3 |
39.7 |
||||
Exceptional items |
– |
– |
– |
–70.0 |
– |
– |
– |
– |
||||
Earnings before interest and tax (EBIT) |
209.5 |
123.4 |
551.1 |
353.8 |
16.2 |
21.4 |
12.3 |
39.7 |
||||
Net operating assets** |
– |
– |
10,672.8 |
10,015.9 |
– |
– |
343.6 |
336.0 |
||||
Segment liabilities** |
– |
– |
–1,143.6 |
–1,078.2 |
– |
– |
–78.2 |
–76.9 |
||||
Capital spending on property, plant and equipment |
53.8 |
71.9 |
161.8 |
192.9 |
1.1 |
1.7 |
3.4 |
6.9 |
||||
Investments in intangible assets |
11.9 |
22.0 |
35.3 |
53.4 |
0.2 |
0.1 |
1.0 |
1.0 |
||||
Depreciation |
–194.2 |
–188.8 |
–564.5 |
–563.1 |
–2.8 |
–3.0 |
–8.8 |
–7.0 |
||||
Impairment losses |
–0.8 |
–0.9 |
–18.0 |
–0.9 |
– |
– |
– |
– |
||||
Net cash flows from operating activities |
471.7 |
401.3 |
1,046.8 |
920.5 |
8.6 |
11.7 |
10.8 |
34.5 |
||||
Net cash flows from investing activities |
–61.3 |
–88.1 |
–187.5 |
–239.4 |
–0.9 |
–0.1 |
–4.5 |
–5.2 |
||||
Free cash flow |
410.4 |
313.2 |
859.3 |
681.0 |
7.7 |
11.5 |
6.3 |
29.3 |
||||
Underlying free cash flow |
410.4 |
313.2 |
859.3 |
681.0 |
7.7 |
11.5 |
6.3 |
29.3 |
||||
FCR in % |
29.5 |
23.8 |
20.2 |
17.2 |
6.1 |
9.4 |
1.8 |
8.8 |
||||
ROS in % |
15.0 |
9.4 |
13.0 |
10.7 |
13.0 |
17.4 |
3.5 |
11.9 |
||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
Pharmaceuticals |
|||||||
EUR million |
|
|
|
|
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||
Sales |
|
|
|
|
1,430.6 |
1,358.6 |
4,336.2 |
4,028.5 |
||||
Royalty and commission income* |
|
|
|
|
87.8 |
82.9 |
261.0 |
258.4 |
||||
Total revenues |
|
|
|
|
1,518.4 |
1,441.5 |
4,597.1 |
4,286.9 |
||||
Gross margin |
|
|
|
|
1,286.0 |
1,186.0 |
3,842.6 |
3,558.3 |
||||
Marketing and selling expenses* |
|
|
|
|
–401.1 |
–366.2 |
–1,222.1 |
–1,122.5 |
||||
Royalty and commission expenses* |
|
|
|
|
–110.7 |
–102.6 |
–341.3 |
–296.5 |
||||
Administration expenses |
|
|
|
|
–73.7 |
–70.1 |
–217.0 |
–215.5 |
||||
Other operating expenses and income |
|
|
|
|
–40.3 |
–60.4 |
–170.0 |
–145.2 |
||||
Research and development |
|
|
|
|
–285.1 |
–297.4 |
–896.6 |
–880.1 |
||||
Operating result |
|
|
|
|
225.7 |
144.8 |
563.4 |
463.5 |
||||
Exceptional items |
|
|
|
|
– |
– |
– |
–70.0 |
||||
Earnings before interest and tax (EBIT) |
|
|
|
|
225.7 |
144.8 |
563.4 |
393.5 |
||||
Net operating assets** |
|
|
|
|
– |
– |
11,016.4 |
10,351.9 |
||||
Segment liabilities** |
|
|
|
|
– |
– |
–1,221.7 |
–1,155.1 |
||||
Capital spending on property, plant and equipment |
|
|
|
|
54.9 |
73.6 |
165.2 |
199.7 |
||||
Investments in intangible assets |
|
|
|
|
12.2 |
22.1 |
36.2 |
54.4 |
||||
Depreciation |
|
|
|
|
–196.9 |
–191.8 |
–573.3 |
–570.1 |
||||
Impairment losses |
|
|
|
|
–0.8 |
–0.9 |
–18.0 |
–0.9 |
||||
Net cash flows from operating activities |
|
|
|
|
480.4 |
413.0 |
1,057.6 |
955.0 |
||||
Net cash flows from investing activities |
|
|
|
|
–62.3 |
–88.2 |
–192.0 |
–244.7 |
||||
Free cash flow |
|
|
|
|
418.1 |
324.8 |
865.6 |
710.3 |
||||
Underlying free cash flow |
|
|
|
|
418.1 |
324.8 |
865.6 |
710.3 |
||||
FCR in % |
|
|
|
|
27.5 |
22.5 |
18.8 |
16.6 |
||||
ROS in % |
|
|
|
|
14.9 |
10.0 |
12.3 |
10.8 |
||||
Segment Reporting – Chemicals* |
||||||||||||||
|
|
|
|
|
|
|
|
|
||||||
|
Merck Millipore |
Performance Materials |
||||||||||||
EUR million |
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||||
|
||||||||||||||
Sales |
571.8 |
224.2 |
1,079.7 |
688.8 |
344.6 |
279.5 |
1,056.7 |
728.3 |
||||||
Royalty and commission income** |
1.9 |
2.4 |
5.6 |
6.6 |
1.1 |
2.3 |
5.6 |
7.5 |
||||||
Total revenues |
573.7 |
226.7 |
1,085.3 |
695.5 |
345.7 |
281.8 |
1,062.3 |
735.8 |
||||||
Gross margin |
295.7 |
104.0 |
565.2 |
324.8 |
236.4 |
138.1 |
713.4 |
338.7 |
||||||
Marketing and selling expenses** |
–141.3 |
–57.2 |
–271.7 |
–171.8 |
–29.9 |
–23.3 |
–85.5 |
–72.6 |
||||||
Royalty and commission expenses** |
–3.2 |
–2.0 |
–6.5 |
–4.9 |
–1.9 |
–0.6 |
–7.5 |
–2.3 |
||||||
Administration expenses |
–27.0 |
–10.2 |
–50.6 |
–32.8 |
–9.8 |
–7.3 |
–28.2 |
–25.9 |
||||||
Other operating expenses and income |
–35.7 |
–5.9 |
–97.6 |
–15.9 |
–9.2 |
–5.6 |
–46.5 |
–26.6 |
||||||
Research and development |
–30.9 |
–8.2 |
–46.0 |
–24.0 |
–32.5 |
–27.2 |
–92.1 |
–82.1 |
||||||
Operating result |
10.0 |
20.2 |
45.2 |
74.6 |
151.9 |
72.6 |
449.4 |
125.0 |
||||||
Exceptional items |
– |
– |
– |
– |
– |
– |
– |
1.2 |
||||||
Earnings before interest and tax (EBIT) |
10.0 |
20.2 |
45.2 |
74.6 |
151.9 |
72.6 |
449.4 |
126.2 |
||||||
Net operating assets*** |
– |
– |
6,493.1 |
781.2 |
– |
– |
1,259.1 |
1,176.3 |
||||||
Segment liabilities*** |
– |
– |
–348.7 |
–111.5 |
– |
– |
–145.3 |
–118.7 |
||||||
Capital spending on property, plant and equipment |
23.6 |
13.1 |
45.5 |
37.4 |
19.5 |
14.1 |
42.9 |
53.5 |
||||||
Investments in intangible assets |
2.1 |
0.7 |
4.3 |
3.6 |
0.7 |
0.4 |
2.1 |
5.0 |
||||||
Depreciation |
–70.3 |
–11.8 |
–95.5 |
–34.0 |
–24.5 |
–20.5 |
–69.5 |
–63.1 |
||||||
Impairment losses |
–1.6 |
– |
–1.6 |
– |
– |
–7.8 |
–16.4 |
–8.0 |
||||||
Net cash flows from operating activities |
29.9 |
56.1 |
95.5 |
143.1 |
184.0 |
131.2 |
468.0 |
242.3 |
||||||
Net cash flows from investing activities |
–4,861.8 |
–12.4 |
–4,886.7 |
–38.5 |
–25.2 |
–33.3 |
–49.5 |
–77.0 |
||||||
Free cash flow |
–4,831.9 |
43.7 |
–4,791.2 |
104.6 |
158.9 |
97.9 |
418.5 |
165.4 |
||||||
Underlying free cash flow |
101.8 |
43.7 |
142.6 |
104.6 |
165.4 |
116.8 |
425.0 |
184.2 |
||||||
FCR in % |
17.8 |
19.3 |
13.1 |
15.0 |
47.9 |
41.4 |
40.0 |
25.0 |
||||||
ROS in % |
1.7 |
8.9 |
4.2 |
10.7 |
43.9 |
25.8 |
42.3 |
17.0 |
||||||
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
Chemicals |
|||||||||
EUR million |
|
|
|
|
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||||
Sales |
|
|
|
|
916.4 |
503.7 |
2,136.4 |
1,417.1 |
||||||
Royalty and commission income** |
|
|
|
|
3.0 |
4.8 |
11.1 |
14.2 |
||||||
Total revenues |
|
|
|
|
919.4 |
508.5 |
2,147.5 |
1,431.3 |
||||||
Gross margin |
|
|
|
|
532.1 |
242.1 |
1,278.6 |
663.5 |
||||||
Marketing and selling expenses** |
|
|
|
|
–171.3 |
–80.4 |
–357.2 |
–244.4 |
||||||
Royalty and commission expenses** |
|
|
|
|
–5.1 |
–2.6 |
–14.0 |
–7.2 |
||||||
Administration expenses |
|
|
|
|
–36.8 |
–17.5 |
–78.9 |
–58.6 |
||||||
Other operating expenses and income |
|
|
|
|
–45.0 |
–11.6 |
–144.1 |
–42.5 |
||||||
Research and development |
|
|
|
|
–63.5 |
–35.4 |
–138.0 |
–106.2 |
||||||
Operating result |
|
|
|
|
161.8 |
92.8 |
494.6 |
199.6 |
||||||
Exceptional items |
|
|
|
|
– |
– |
– |
1.2 |
||||||
Earnings before interest and tax (EBIT) |
|
|
|
|
161.8 |
92.8 |
494.6 |
200.8 |
||||||
Net operating assets*** |
|
|
|
|
– |
– |
7,752.2 |
1,957.4 |
||||||
Segment liabilities*** |
|
|
|
|
– |
– |
–494.1 |
–230.2 |
||||||
Capital spending on property, plant and equipment |
|
|
|
|
43.1 |
27.2 |
88.5 |
90.9 |
||||||
Investments in intangible assets |
|
|
|
|
2.8 |
1.0 |
6.4 |
8.6 |
||||||
Depreciation |
|
|
|
|
–94.8 |
–32.3 |
–164.9 |
–97.1 |
||||||
Impairment losses |
|
|
|
|
–1.6 |
–7.8 |
–18.0 |
–8.0 |
||||||
Net cash flows from operating activities |
|
|
|
|
213.9 |
187.4 |
563.5 |
385.5 |
||||||
Net cash flows from investing activities |
|
|
|
|
–4,886.9 |
–45.8 |
–4,936.2 |
–115.5 |
||||||
Free cash flow |
|
|
|
|
–4,673.0 |
141.6 |
–4,372.7 |
269.9 |
||||||
Underlying free cash flow |
|
|
|
|
267.3 |
160.5 |
567.6 |
288.8 |
||||||
FCR in % |
|
|
|
|
29.1 |
31.6 |
26.4 |
20.2 |
||||||
ROS in % |
|
|
|
|
17.6 |
18.2 |
23.0 |
13.9 |
||||||
Segment Reporting – Corporate and Other/Merck Group |
|
|||||||||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
Corporate and Other |
|||||||
EUR million |
|
|
|
|
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||
|
||||||||||||
Sales |
|
|
|
|
– |
– |
– |
– |
||||
Royalty and commission income* |
|
|
|
|
– |
– |
– |
– |
||||
Total revenues |
|
|
|
|
– |
– |
– |
– |
||||
Gross margin |
|
|
|
|
– |
– |
– |
– |
||||
Marketing and selling expenses* |
|
|
|
|
–1.0 |
0.5 |
–2.4 |
0.1 |
||||
Royalty and commission expenses* |
|
|
|
|
– |
–0.1 |
– |
- |
||||
Administration expenses |
|
|
|
|
–17.4 |
–14.4 |
–51.6 |
–42.8 |
||||
Other operating expenses and income |
|
|
|
|
–5.7 |
–4.8 |
–21.3 |
–18.9 |
||||
Research and development |
|
|
|
|
– |
– |
– |
– |
||||
Operating result |
|
|
|
|
–24.1 |
–15.4 |
–73.6 |
–58.3 |
||||
Exceptional items |
|
|
|
|
– |
– |
–1.2 |
– |
||||
Earnings before interest and tax (EBIT) |
|
|
|
|
–24.1 |
–15.4 |
–74.8 |
–58.3 |
||||
Net operating assets** |
|
|
|
|
– |
– |
25.1 |
37.4 |
||||
Segment liabilities** |
|
|
|
|
– |
– |
–17.6 |
–15.7 |
||||
Capital spending on property, plant and equipment |
|
|
|
|
0.3 |
0.1 |
0.6 |
– |
||||
Investments in intangible assets |
|
|
|
|
1.6 |
2.2 |
4.9 |
7.6 |
||||
Depreciation |
|
|
|
|
–1.2 |
–0.4 |
–2.3 |
–1.3 |
||||
Impairment losses |
|
|
|
|
– |
– |
– |
– |
||||
Net cash flows from operating activities |
|
|
|
|
–136.2 |
–64.8 |
–318.1 |
–329.9 |
||||
Net cash flows from investing activities |
|
|
|
|
48.8 |
–35.9 |
1,384.8 |
–1,076.2 |
||||
Free cash flow |
|
|
|
|
–127.9 |
–67.4 |
–324.6 |
–338.0 |
||||
Underlying free cash flow |
|
|
|
|
–124.6 |
–55.8 |
–305.9 |
–326.4 |
||||
FCR in % |
|
|
|
|
– |
– |
– |
– |
||||
ROS in % |
|
|
|
|
– |
– |
– |
– |
||||
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
Merck Group |
|||||||
EUR million |
|
|
|
|
Q3 |
Q3 |
Jan.-Sep. |
Jan.-Sep. |
||||
Sales |
|
|
|
|
2,347.0 |
1,862.3 |
6,472.6 |
5,445.6 |
||||
Royalty and commission income* |
|
|
|
|
90.8 |
87.7 |
272.1 |
272.6 |
||||
Total revenues |
|
|
|
|
2,437.8 |
1,950.0 |
6,744.7 |
5,718.2 |
||||
Gross margin |
|
|
|
|
1,818.2 |
1,428.1 |
5,121.2 |
4,221.8 |
||||
Marketing and selling expenses* |
|
|
|
|
–573.3 |
–446.2 |
–1,581.7 |
–1,366.8 |
||||
Royalty and commission expenses* |
|
|
|
|
–115.8 |
–105.2 |
–355.3 |
–303.8 |
||||
Administration expenses |
|
|
|
|
–128.0 |
–102.0 |
–347.5 |
–316.9 |
||||
Other operating expenses and income |
|
|
|
|
–91.0 |
–76.8 |
–335.4 |
–206.6 |
||||
Research and development |
|
|
|
|
–348.6 |
–332.8 |
–1,034.6 |
–986.3 |
||||
Operating result |
|
|
|
|
363.5 |
222.2 |
984.4 |
604.8 |
||||
Exceptional items |
|
|
|
|
– |
– |
–1.2 |
–68.8 |
||||
Earnings before interest and tax (EBIT) |
|
|
|
|
363.5 |
222.2 |
983.2 |
536.0 |
||||
Net operating assets** |
|
|
|
|
– |
– |
18,793.7 |
12,346.7 |
||||
Segment liabilities** |
|
|
|
|
– |
– |
–1,733.3 |
–1,401.0 |
||||
Capital spending on property, plant and equipment |
|
|
|
|
98.3 |
101.0 |
254.2 |
290.6 |
||||
Investments in intangible assets |
|
|
|
|
16.5 |
25.4 |
47.6 |
70.7 |
||||
Depreciation |
|
|
|
|
–292.9 |
–224.5 |
–740.5 |
–668.3 |
||||
Impairment losses |
|
|
|
|
–2.4 |
–8.7 |
–36.0 |
–8.9 |
||||
Net cash flows from operating activities |
|
|
|
|
558.0 |
535.5 |
1,302.9 |
1,010.5 |
||||
Net cash flows from investing activities |
|
|
|
|
–4,900.5 |
–169.8 |
–3,743.4 |
–1,436.4 |
||||
Free cash flow |
|
|
|
|
–4,382.9 |
399.0 |
–3,831.7 |
642.2 |
||||
Underlying free cash flow |
|
|
|
|
560.7 |
429.5 |
1,127.3 |
672.7 |
||||
FCR in % |
|
|
|
|
23.0 |
22.0 |
16.7 |
11.8 |
||||
ROS in % |
|
|
|
|
14.9 |
11.4 |
14.6 |
10.6 |
||||